Last 39 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.73 | — | — | — | — | — | 6.81 | — | — | — | — | — | — | — | — | 0.39 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | 13.02 | — | — | — | — | 0.33 | 4.83 | 4.92 | 11.76 | 10.57 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -96.9% | — | -99.8% | -95.1% | -99.2% | — | |
| P/B Ratio | 1.52 | 13.57 | 12.91 | 8.69 | 3.73 | 5.02 | 7.25 | 12.17 | 16.48 | 8.58 | 11.80 | 8.28 | 6.92 | 5.69 | 2.00 | 1.91 | — | 41.83 | 37.29 | 7.97 | 37.81 |
| — | +170.4% | +78.2% | -28.5% | -77.4% | -41.5% | -38.6% | +47.0% | +138.1% | +50.8% | +490.5% | +332.5% | — | -86.4% | -94.6% | -76.0% | — | +132.1% | +94.8% | -36.5% | +263.7% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 27.51 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | 5.94 | — | — | — | — | — | — | — | — | 0.36 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.37 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | 100.0% | — | — | — | — | 95.1% | -138.3% | -173.1% | 100.0% | -439.0% | 547.6% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +121.7% | -125.3% | +98.7% | +110.8% | +93.7% | +447.6% | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | -167.2% | — | — | — | — | 85.4% | -258.2% | -302.8% | -301.6% | -635.0% | 627.7% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +113.4% | -141.1% | +98.3% | +75.3% | +92.9% | +268.1% | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | -165.8% | — | — | — | — | 84.5% | -256.0% | -302.3% | -325.5% | -652.7% | 640.0% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +112.9% | -140.0% | +98.3% | +74.0% | +92.8% | +277.2% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -92.5% | -72.9% | -60.7% | -53.4% | -30.9% | -25.9% | 33.2% | -172.7% | -69.1% | -31.4% | -31.7% | -39.5% | -74.0% | -47.4% | -29.8% | 327.9% | — | -339.6% | -115.4% | -109.7% | -93.0% |
| — | -181.6% | -283.0% | +69.1% | +55.3% | +17.6% | +204.8% | -337.2% | +6.6% | +33.7% | -6.1% | -112.0% | — | +86.0% | +74.1% | +399.1% | — | -931.6% | -415.8% | -483.2% | -717.6% | |
| ROA | -34.0% | -9.3% | -13.6% | -19.8% | -14.3% | -13.3% | 16.8% | -55.9% | -10.2% | -5.6% | -7.4% | -12.1% | -34.5% | -27.8% | -18.6% | 70.4% | -15.7% | -18.9% | -15.6% | -19.4% | -30.9% |
| — | +30.2% | -181.0% | +64.6% | -40.0% | -137.1% | +326.5% | -361.2% | +70.3% | +79.8% | +60.1% | -117.2% | -120.0% | -46.6% | -19.2% | +463.4% | +49.3% | -7.8% | -18.1% | -61.6% | -263.1% | |
| ROIC | -2734.3% | — | — | -105.4% | -82.7% | -122.9% | 248.5% | -151.2% | -24.5% | -11.1% | -7.3% | -11.6% | -20.1% | -32.3% | -26.7% | 1590.1% | — | — | — | — | -256.7% |
| — | — | — | +30.3% | -237.2% | -1010.3% | +3511.4% | -1198.0% | -22.1% | +65.7% | +72.8% | -100.7% | — | — | — | — | — | — | — | — | -2519.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | — | 0.01 | 0.04 | 0.05 | 0.05 | 0.05 | 0.88 | 3.97 | 4.54 | 2.94 | 2.20 | 1.52 | 0.72 | 0.49 | 0.49 | — | 6.53 | 2.39 | 1.31 | 1.77 |
| — | — | -80.7% | -94.9% | -98.7% | -98.8% | -98.2% | -60.1% | +161.1% | +528.8% | +501.0% | +349.1% | — | -89.0% | -79.5% | -62.7% | — | +635.5% | +266.3% | +225.8% | +296.3% | |
| Debt / EBITDA | — | — | — | — | — | — | 0.20 | — | — | — | — | — | — | — | — | 0.39 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.19 | 0.56 | 0.79 | 1.19 | 1.96 | 1.89 | 2.91 | 4.45 | 0.71 | 0.61 | 0.55 | 0.81 | 1.39 | 2.56 | 4.13 | 6.13 | 0.67 | 1.26 | 1.37 | 1.28 | 2.92 |
| — | -70.6% | -72.8% | -73.3% | +176.1% | +212.3% | +428.7% | +452.1% | -48.9% | -76.3% | -86.7% | -86.9% | +108.0% | +103.6% | +202.5% | +378.4% | -77.1% | -73.6% | -76.4% | -79.6% | -62.0% | |
| Quick Ratio | 1.19 | 0.56 | 0.79 | 1.19 | 1.96 | 1.89 | 2.91 | 4.45 | 0.71 | 0.61 | 0.55 | 0.81 | 1.39 | 2.56 | 4.13 | 6.13 | 0.67 | 1.26 | 1.37 | 1.28 | 2.82 |
| — | -70.6% | -72.8% | -73.3% | +176.1% | +212.3% | +428.7% | +452.1% | -48.9% | -76.3% | -86.7% | -86.9% | +108.0% | +103.6% | +202.5% | +378.4% | -76.3% | -71.9% | -74.7% | -79.6% | -62.8% | |
| Interest Coverage | -5579.00 | — | — | -3531.00 | — | — | — | — | -89.25 | -99.00 | — | — | — | — | — | — | — | — | -13.03 | -35.67 | -50.73 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 39 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying XCUR stock.
Exicure, Inc.'s current P/E is -0.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Exicure, Inc.'s business trajectory between earnings reports.